Semaglutide Preserves Muscle Mass and Metabolic Rate Better Than Dieting Alone in Obese Minipigs | Research

The takeaway

Semaglutide mitigated the loss of fat-free mass and energy expenditure decline seen with calorie restriction alone in an obese minipig model.

Muscle + metabolism preserved
Semaglutide maintained fat-free mass and energy expenditure vs diet restriction alone

What the researchers found

Semaglutide treatment preserved fat-free mass and energy expenditure compared to diet restriction alone in obese minipigs, demonstrating more favorable body composition changes.

Why it matters

Critics worry GLP-1 drugs cause excessive muscle loss. This data suggests semaglutide actually preserves muscle better than equivalent calorie restriction, addressing a key safety concern.

How the study worked

Controlled study in diet-induced obese Göttingen minipigs (n=8/group): control (ad libitum), semaglutide-treated, and diet-restricted groups, measuring body composition and energy expenditure.

What this study cannot tell us

Minipig model — not human data. Small group sizes (n=8). Short study duration may not capture long-term body composition changes.

How to read the evidence

Preclinical animal study using a translational obesity model — provides valuable mechanistic data but needs human confirmation.

When this study was published

Published in 2026; uses the Göttingen minipig, considered one of the best large animal models for human obesity.

The bigger picture

This challenges the narrative that GLP-1 drugs cause harmful muscle loss, suggesting the body composition profile of pharmacological weight loss may be superior to dieting.

Questions still open

Do human studies confirm that semaglutide preserves muscle mass compared to dieting?
Does preserved muscle mass translate to better functional outcomes?

Common questions

Does semaglutide cause muscle loss?

This minipig study actually shows semaglutide preserves more muscle mass than equivalent calorie restriction. Some muscle loss occurs with any weight loss, but semaglutide may produce a better ratio of fat to muscle loss.

Why use minipigs for this research?

Göttingen minipigs closely mimic human obesity in body fat distribution, metabolism, and response to weight loss treatments, making them one of the best animal models for obesity research.

Read the original research

Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.

American journal of physiology. Endocrinology and metabolism

View on PubMed ↗Publisher’s paper ↗

Citation

Bredum, Simon Krogh; Jacobsen, Julie M; Halling, Jens Frey; Blom, Ida; Lewis, Christopher T A; Ochala, Julien; Fredholm, Merete; Lundh, Sofia; Schmücker, Malte; Ozenne, Brice; Domingos, Ana I; Hald, Bjørn Olav; Larsen, Steen; Cirera, Susanna; Christoffersen, Berit Oestergaard. (2026). Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.. American journal of physiology. Endocrinology and metabolism. https://doi.org/10.1152/ajpendo.00480.2024